Other headlines for [MDT]

• MDT 11/19/2008 08:21am
  Medtronic Inc Price target cut to $44 from $62 at Stifel, maintains buy rating
  
• MDT 11/19/2008 06:43am
  Medtronic Inc Price Target lowered to $50 from $60 at Merrill, maintains buy rating
  
• MDT 11/19/2008 00:17am
  Medtronic Inc The DoJ is probing the off-label use of the company's INFUSE bone growth product - WSJ- The regulators are investigating the use of INFUSE for the treatment of heart problems. - The safety concerns more...
  
• MDT 11/18/2008 08:34am
  Medtronic Inc Cuts FY09 EPS guidance to $2.90-2.98 v $2.99e ($2.94-3.02 prior), R $14.6-15B v $15.2Be- EPS cut due to first factor is a $0.03 per share charge associated with the write off of inventory made more...
  
• MDT 11/18/2008 08:12am
  Medtronic Inc CEO: Confident in double digit EPS growth in H209 - conf call- Says have received DoJ subpoena regarding spine product
  

Healthcare sector headlines

• NABI Today 09:15am
  Nabi Biopharmaceuticals Increases patent portfolio with receipt of two patents for components of PentaStaph- European Patent Office issued Patent EP No. 0 925 073 that provides composition-of-matter protection in the EU more...
  
• HOLX Today 09:12am
  Hologic, Inc. Price Target lowered to $22 from $24 at Lazard, maintains buy rating
  
• CORT Today 09:00am
  Corcept Therapeutics Incorpora Names Caroline Loewy as new CFO- Ms. Loewy most recently served as CFO of Poniard Pharmaceuticals, a publicly traded biopharmaceutical company, where she was a key driver of that company's corporate more...
  
• LHCG Today 08:57am
  LHC Group Guides FY09 EPS $1.90-2.00 v $1.93e, R $450M-$470M v $436.2Me
  
• NPSP Today 08:50am
  NPS Pharmaceuticals Inc. Update: Initiates Phase 3 'STEPS' Study to Confirm GATTEX Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome- Patient enrollment has begun in a Phase 3 registrational study to confirm more...